This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB04836/identifier/chemspider/
n16http://linked.opendata.cz/resource/mesh/concept/
n14http://linked.opendata.cz/resource/drugbank/drug/DB04836/identifier/chebi/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04836/identifier/wikipedia/
n8http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n13http://linked.opendata.cz/resource/drugbank/drug/DB04836/identifier/pubchem-compound/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n11http://linked.opendata.cz/resource/drugbank/drug/DB04836/identifier/pubchem-substance/
n15http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n12http://linked.opendata.cz/resource/drugbank/drug/DB04836/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB04836
rdf:type
n3:Drug
n3:description
The Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until 2005.
n3:generalReferences
# Vaugeois JM, Corera AT, Deslandes A, Costentin J: Although chemically related to amineptine, the antidepressant tianeptine is not a dopamine uptake inhibitor. Pharmacol Biochem Behav. 1999 Jun;63(2):285-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10371658 # Grupper C: [New iatrogenic acne: acne caused by amineptin (Survector)] Ann Dermatol Venereol. 1988;115(11):1174-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2977079 # Thioly-Bensoussan D, Charpentier A, Triller R, Thioly F, Blanchet P, Tricoire N, Noury JY, Grupper C: [Iatrogenic acne caused by amineptin (Survector). Apropos of 8 cases] Ann Dermatol Venereol. 1988;115(11):1177-80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2977080 # Vexiau P, Gourmel B, Husson C, Castot A, Rybojad M, Julien R, Fiet J, Puissant A, Cathelineau G: [Severe lesions of acne type induced by chronic amineptin poisoning: apropos of 6 cases] Ann Dermatol Venereol. 1988;115(11):1180-2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2977081 # Teillac D, Weber MJ, Lowenstein W, de Prost Y: [Acne caused by Survector] Ann Dermatol Venereol. 1988;115(11):1183-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2977082
n3:group
illicit withdrawn
n3:halfLife
48 minutes for the parent drug and 2.5 hours for the metabolites.
n3:indication
For the treatment of depression.
owl:sameAs
n6:DB04836 n8:DB04836
dcterms:title
Amineptine
adms:identifier
n10:Amineptine n11:46509012 n12:DB04836 n13:34869 n14:32499 n17:32090
n3:mechanismOfAction
Amineptine selectively inhibits the reuptake of dopamine and to a lesser extent norepinephrine, thus exerting a powerful and fast-acting antidepressant effect.
n3:foodInteraction
Avoid alcohol. Avoid excessive quantities of coffee or tea (Caffeine). Avoid St.John's Wort. Take with food to reduce irritation.
n3:salt
n3:synthesisReference
Melen,C., Danree, B.and Poignant, J.C.; US.Patent 3,758,528; September 11,1973; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale. Melen, C., Danree, B. and Poignant, J.C.; U.S. Patent 3,821,249; June 28, 1974; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale.
n15:hasConcept
n16:M0058027
n3:IUPAC-Name
n4:271B5852-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5858-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5857-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5854-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5855-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5856-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5850-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B584E-363D-11E5-9242-09173F13E4C5 n4:271B5851-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B584F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B585E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B585F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5859-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B585A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B585C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B585B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B585D-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
57574-09-1
n3:Bioavailability
n4:271B5864-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5866-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5867-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5868-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5863-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5862-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5865-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5853-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5860-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5861-363D-11E5-9242-09173F13E4C5